Safety data from a phase II trial of Radium-223 dichloride plus Enzalutamide versus Enzalutamide alone in men with metastatic castration refractory prostate cancer
Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic castration refractory prostate cancer ( mCRPC ).
Per SWOG0421, the subset of men with mCRPC with the highest bone metabolism marker levels had improved survival with concomitant decrease in these markers on treatment ( Rx ) with Atrasentan, a bone targeting agent ( Lara P et al, JNCI, 2014 ).
The hypothesis was that tretament with Radium-223 + Enzalutamide will be safe and feasible, and decrease bone metabolism markers compared to Enzalutamide alone.
In a phase 2 trial, men with progressive CRPC on continuous androgen deprivation therapy were included.
Radium-223 was administered at standard dose of 55 kBq/kg IV Q4 weeks x 6, and Enzalutamide at 160 mg orally daily until disease progression or unacceptable toxicities.
Primary objectives were: 1) safety and feasibility of combining Radium-223 + Enzalutamide, 2) changes in the bone metabolism markers with treatment.
Secondary objectives included time to progression, skeletal events, percent change in opioid use.
The pre-specified primary safety endpoint was the proportion of patients treated with the combination who experienced grade 3+ cytopenias relative to historic controls ( 21% ) from the phase 3 ALSYMPCA trial using an exact binomial test with a one-sided 0.05 significance level.
All adverse events between arms were compared using Fisher’s Exact Test.
Safety data were presented. 49 patients were accrued between 2014-2017. 35 men received treatment with Radium-223 + Enzalutamide and 14 men with Enzalutamide alone.
The primary safety endpoint occurred in 3 patients in the combination arm ( incidence 8.6%, n = 35 patients ), and in 0 patients in the Enzalutamide only arm ( n=14 ).
These were similar to historic data ( ALSYMPCA trial ) of monotherapy with Radium-223 ( P = 1.00 ), and not different between arms ( P=0.55 ).
Serious adverse events, regardless of attribution were similar in both arms ( P=0.66 ).
In conclusion, combining Radium-223 + Enzalutamide is safe and feasible in men with progressive mCRPC with no difference observed in serious adverse events regardless of attribution between two arms.
Specifically, there was no incidence of skeletal related events in either arm. ( Xagena )
Source: ASCO ( American Society of Clinical Oncology ) Meeting, 2018
Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...
Apalutamide vs placebo in patients with non-metastatic castration-resistant prostate cancer receiving androgen deprivation therapy: health-related quality of life at final analysis of the SPARTAN study
The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...
European Union: Lynparza approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...
Apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer: final survival results from SPARTAN, a phase III trial
SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...
Darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer: overall survival results of phase III ARAMIS study
Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...
IPATential150 study: Ipatasertib in combination with Abiraterone and Prednisone / Prednisolone met its co-primary endpoint of radiographic progression free survival in patients with PTEN loss tumours
Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...
Erleada for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease, European Commission approved
The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...
Apalutamide improves overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer
Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...
For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...